A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Pier Luigi Zinzani, Stephen M. Ansell, Francesc Bosch, Jonathan W. Friedberg, Jean pierre Marolleau, Luca Arcaini, Ramón Garcia-Sanz, Ajay K. Gopal, Carlos Grande, Reid Merryman, Antonio Pinto, Stephen D. Smith, Jose Caetano Villasboas, Danielle Wallace, Jan Fagerberg, Joao Magalhaes, Philippe Armand
Institutions: University of Bologna, Mayo Clinic, Vall d'Hebron Hospital Universitari, University of Rochester Medicine, Centre Hospitalier Universitaire Amiens-Picardie, University of Pavia, Policlinico San Matteo Fondazione, Complejo Hospitalario de Salamanca, University of Washington, Universidad de Navarra, Dana-Farber Cancer Institute, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Fred Hutch Cancer Center, University of Rochester, Enterome (France)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281680519